Abstract:
L'invention se rapporte à de nouveaux antigènes de peptides de HTLV-I et HTLV-II s'utilisant dans des analyses diagnostiques servant à évaluer et à confirmer les antisérums de HTLV-I et HTLV-II. Les peptides sont dérivés de régions analogues de protéines enveloppantes de HTLV-I et HTLV-II gp 46 et sont différenciés par leur immunoréactivité à un anticorps monoclonal spécifique de HTLV-I et par leurs antisérums de HTLV-I et HTLV-II. Lesdits peptides sont également efficaces dans des compositions de vaccins.
Abstract:
Un procédé induisant une immunité active contre une maladie virale chez un sujet animal, consiste à administrer au sujet un conjugué de vaccin composé essentiellement d'un virus vivant et d'un facteur neutralisant lié au virus vivant. Le facteur neutralisant est choisi dans le groupe composé d'anticorps et de fragments d'anticorps. Le virus vivant est du type capable d'induire une maladie chez un sujet, et l'anticorps ou le fragment d'anticorps est du type capable de neutraliser le virus vivant. Les sujets préférés sont les oiseaux, un virus préféré est le virus de la maladie de la bourse infectieuse, et une voie d'administration préférée à des oiseaux est la voie in ovo.
Abstract:
Transdominant repressors of viral gene phenotypic expression derived from the rev gene product of HIV-1 or the rex gene product of HTLV-1 and corresponding mutated genes are described', having the capability of repressing the Rev function in HIV-1 and/or the Rex function in HTLV-I and HTLV-II. Transient gene expression analysis of a series of missense and deletion mutants has been used. Some of the mutants found repress both the Rev and the Rex function and are thus active in more than one viral species. Transdominant viral mutants represent a promising new class of anti-viral agents. Cellular expression of these transdominant inhibitors may be used in such therapeutic approaches as intracellular immunization in order to protect cells against the deleterious effects of viral, e.g. HIV-1 infection.
Abstract:
An antibody of a human leukemia virus-related peptide obtainable by collecting an antibody produced in a mammal body by administering to the mammal an antigen prepared by reacting a human leukemia virus-related peptide selected from the group consisting of:
a peptide represented by formula (1): wherein R is a hydrogen atom or a group shown by formula, H-Tyr-; a peptide represented by formula (2): a peptide represented by formula (3): wherein R is the same as defined above; I a peptide represented by formula (4): (4) wherein R is the same as defined above; a peptide represented by formula (5): a peptide represented by formula (6): wherein R is the same as defined above; and a peptide represented by formula (7): as a hapten, with a carrier in the presence of a hapten-carrier binding agent. Also disclosed is the method of obtaining the antibody and specific peptides.
Abstract:
The invention relates to a process for the production of peptides which bind to a predetermined specific binding partner, which includes the setting up of a nucleotide bank, the transformation of microorganisms, the cultivation of the transformed microorganisms and the selection of the microorganisms which express the peptides which are sought, and to the use of such peptides.